Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients

Metabolism: Clinical and Experimental

Volumn 63, Issue 11, 2014, Pages 1439-1446

  Marzano, Luigi ^a   Colussi, Gianluca ^a   Del Torre, Martina ^a   Sechi, Leonardo A ^a   Catena, Cristiana ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Hyperinsulinemia; Hypertension; Insulin resistance; Lipoprotein(a); Oral glucose tolerance test

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DIURETIC THERAPY; DRUG USE; FEMALE; GLUCOSE METABOLISM; HOMEOSTATIC MODEL ASSESSMENT INDEX; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; SEX RATIO; SMOKING HABIT; AGED; BLOOD; PATHOPHYSIOLOGY;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIPOPROTEIN(A); MALE; MIDDLE AGED;

EID: 84908010648     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.08.007     Document Type: Article

References (46)

1. A.M. Scanu, R.M. Lawn, and K. Berg Lipoprotein(a) and atherosclerosis Ann Intern Med 115 1991 209 218
2. S.M. Marcovina, V.P. Gaur, and J.J. Albers Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B Clin Chem 40 1994 574 578
3. L.A. Sechi, L. Zingaro, C. Catena, A. Perin, S. De Marchi, and E. Bartoli Lipoprotein(a), apolipoprotein(a) isoforms, and proteinuria in patients with moderate renal failure Kidney Int 56 1999 1049 1057
4. M. O'Donoghue, D.A. Morrow, S. Tsimikas, S. Sloan, A.F. Ren, and E.B. Hoffman Lipoprotein(a) for risk assessment in patients with established coronary artery disease J Am Coll Cardiol 63 2014 520 527
5. P.J. Nestel, E.H. Barnes, A.M. Tonkin, J. Simes, M. Fournier, and H.D. White Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease Arterioscler Thromb Vasc Biol 33 2013 2902 2908
6. S. Tselmin, U. Julius, G. Muller, S. Fischer, and S.R. Bornstein Cardiovascular events in patients with increased lipoprotein(a) - retrospective data analysis in an outpatient department of lipid disorders Atheroscler Suppl 10 2009 79 84
7. L.A. Sechi, F. Kronenberg, S. De Carli, E. Falleti, L. Zingaro, and C. Catena Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension JAMA 277 1997 1689 1695
8. C. Catena, M. Novello, R. Lapenna, S. Baroselli, G.L. Colussi, and E. Nadalini New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a) J Hypertens 23 2005 1617 1631
9. L.A. Sechi, A. Melis, and R. Tedde Insulin hypersecretion: a distinctive feature between essential and secondary hypertension Metabolism 41 1992 1261 1266
10. G. Reaven Insulin resistance, hypertension, and coronary heart disease J Clin Hypertens 5 2003 269 274
11. M. Boronat, P. Saavedra, N. Perez-Martin, M.J. Lopez-Madrazo, C. Rodriguez-Perez, and F.J. Novoa High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain Cardiovasc Diabetol 11 2012 81
12. D.L. Rainwater, and S.M. Haffner Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype Arterioscler Thromb Vasc Biol 18 1998 1335 1341
13. M. Sidhu, D. Crook, I.F. Godsland, C. Walton, V. Wynn, and M.F. Oliver Inverse relationship between serum Lp(a) levels and first-phase insulin secretion Diabetes 41 1992 1341 1345
14. C. Catena, L. Zingaro, D. Casaccio, and L.A. Sechi Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance Am J Med 109 2000 556 561
15. L.A. Sechi, L. Zingaro, C. Catena, and S. De Marchi Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events Thromb Haemost 84 2000 865 870
16. F. Dati, J.R. Tate, S.M. Marcovina, and A. Steinmetz First WHO/IFCC International reference reagent for lipoprotein(a) for immunoassay-Lp(a) SRM 2B Clin Chem Lab Med 42 2004 670 676
17. L.A. Sechi, C. Catena, L. Zingaro, A. Melis, and S. De Marchi Abnormalities of glucose metabolism in patients with early renal failure Diabetes 51 2002 1226 1232
18. National Heart LaBIaBUFHS General Cardiovascular Disease (10-year risk). Last update February 7, 2013 2013
19. S.M. Grundy, H.B. Brewer Jr., J.I. Cleeman, S.C. Smith Jr., and C. Lenfant Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 2004 433 438
20. J. Hoover-Plow, and M. Huang Lipoprotein(a) metabolism: potential sites for therapeutic targets Metabolism 62 2013 479 491
21. E. Boerwinkle, C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H.H. Hobbs Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations J Clin Invest 90 1992 52 60
22. B. Kolski, and S. Tsimikas Emerging therapeutic agents to lower lipoprotein(a) levels Curr Opin Lipidol 23 2012 560 568
23. M. Seed, B. O'Conner, N. Perombelon, M. O'Donnell, D. Reaveley, and B.L. Knight The effects of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover Atherosclerosis 101 1993 61 68
24. I. Gouni-Berthold, and H.K. Berthold Lipoprotein(a): current perspectives Curr Vasc Pharmacol 9 2011 682 692
25. C. Catena, M. Novello, L. Dotto, S. De Marchi, and L.A. Sechi Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage J Hypertens 21 2003 281 288
26. G.L. Colussi, S. Baroselli, and L.A. Sechi Omega-3 polyunsaturated fatty acids decrease plasma lipoprotein(a) levels in hypertensive subjects Clin Nutr 3 2004 1246 1247
27. L.A. Sechi, C. Catena, D. Casaccio, and L. Zingaro Lipoprotein(a), hemostatic variables, and cardiovascular damage in hypertensive patients J Hypertens 18 2000 709 716
28. S.M. Haffner, K.R. Tuttle, and D.L. Rainwater Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects Diabetes Care 14 1991 302 307
29. S.S. Habib, M. Aslam, S.F. Shah, and A.K. Naveed Lipoprotein(a) is associated with basal insulin levels in patients with type 2 diabetes mellitus Arq Bras Cardiol 93 2009 28 33
30. P.B. Duell, F. Hagemenas, and W.E. Connor The relationship between serum lipoprotein(a) and insulinemia in healthy nondiabetic adult men Diabetes Care 17 1994 1135 1140
31. C. Posadas-Romero, A. Hernandez-Ono, J. Zamora-Gonzalez, G. Cardoso-Saldana, L. Yamamoto-Kimura, and O.R. Brito-Zurita Differential effects of obesity with and without hyperinsulinemia on plasma lipoprotein(a) concentrations in men Metabolism 50 2001 178 183
32. A.L. Mark, and E.A. Anderson Genetic factors determine the blood pressure response to insulin resistance and hyperinsulinemia: a call to refocus the insulin hypothesis of hypertension Proc Soc Exp Biol Med 208 1995 330 336
33. C. Catena, A. Cavarape, M. Novello, G. Giacchetti, and L.A. Sechi Insulin receptors and renal sodium handling in fructose-fed rats Kidney Int 64 2003 2163 2171
34. D.M. Neele, E.C. de Wit, and H.M. Princen Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes Diabetologia 42 1999 41 44
35. J.J. Albers, M.L. Koschinsky, and S.M. Marcovina Evidence mounts for a role of the kidney in lipoprotein(a) catabolism Kidney Int 71 2007 961 962
36. G. Derosa, I. Franzetti, G. Gadaleta, L. Ciccarelli, and R. Fogari Metabolic variations with oral antidiabetic drugs in patients with type 2 diabetes: comparison between glimepiride and metformin Diabetes Nutr Metab 17 2004 143 150
37. S.S. Habib, M. Aslam, A.K. Naveed, and M.S. Razi Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy Saudi Med J 27 2006 174 180
38. G. Derosa, A.V. Gaddi, L. Ciccarelli, R. Fogari, M. Ghelfi, and I. Ferrari Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin- treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial J Int Med Res 33 2005 284 294
39. V.A. Fonseca, P. Theuma, S. Mudaliar, C.A. Leissinger, S. Clejan, and R.R. Henry Diabetes treatments have differential effects on nontraditional cardiovascular risk factors J Diabetes Complications 20 2006 14 20
40. K. Matsumoto, S. Miyake, M. Yano, Y. Ueki, and Y. Tominaga Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone Metabolism 48 1999 1 2
41. M. Igarashi, Y. Jimbu, M. Kimura, A. Hirqata, H. Yamaguchi, and M. Tominaga Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders Diabetes Res Clin Pract 77 2007 389 398
42. G. Derosa, A.F. Cicero, A. D'Angelo, A. Gaddi, L. Ciccarelli, and M.N. Piccinni Effects of 1 year treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein(a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial Clin Ther 28 2006 679 688
43. G. Derosa, A. D'Angelo, P.D. Ragonesi, L. Ciccarelli, M.N. Piccinni, and F. Pricolo Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome J Clin Pharm Ther 31 2006 375 383
44. G. Derosa, A. D'Angelo, E. Fogari, S.A. Salvadeo, A. Gravina, and I. Ferrari Effects of natiglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized trial Intern Med 46 2007 1837 1846
45. P.A. Sarafidis, A.N. Lasaridis, P.M. Nilsson, T.F. Mouslech, A.D. Hitoglou-Makedou, and P.C. Stafylas The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study Metabolism 54 2005 1236 1242
46. Y. Sahin, K. Unluhizarci, A. Yilmazsoy, A. Yikilmaz, E. Aygen, and F. Kelestimur The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome Clin Endocrinol 67 2007 904 908